<DOC>
	<DOCNO>NCT01791192</DOCNO>
	<brief_summary>This study ass safety , tolerability , efficacy FTY720 patient acute , noninfectious intermediate , posterior pan uveitis</brief_summary>
	<brief_title>Study FTY720 Patients With Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Acute noninfectious posterior , intermediate , pan uveitis Vitreous haze score 1+ study eye screen baseline visit Vasoocclusive vasculitis involve retinal macula Beh√ßet 's uveitis Patients require corticosteroid another systemic immunosuppressive medication disease ( e.g. , asthma autoimmune disease ) would contraindicate tapering ( topical steroid permit ) Other protocol define inclusion and/or exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Uveitis , Fingolimod , Phase II , Visual Acuity , Vitreous Haze , OCT</keyword>
</DOC>